Found: 26
Select item for more details and to access through your institution.
Erratum to: Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
- Published in:
- 2017
- By:
- Publication type:
- corrected article
Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden.
- Published in:
- 2016
- By:
- Publication type:
- journal article
The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.
- Published in:
- 2005
- By:
- Publication type:
- journal article
Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Phase II Trial of Romidepsin as Consolidation Therapy after Gemcitabine, Dexamethasone, and Cisplatin in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.
- Published in:
- Hematology Reports, 2024, v. 16, n. 2, p. 336, doi. 10.3390/hematolrep16020034
- By:
- Publication type:
- Article
Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
- Published in:
- International Journal of Clinical Oncology, 2019, v. 24, n. 8, p. 966, doi. 10.1007/s10147-019-01436-8
- By:
- Publication type:
- Article
Treatment of hepatic amyloid light-chain amyloidosis with bortezomib and dexamethasone in a liver transplant patient.
- Published in:
- Hepatology Research, 2015, v. 45, n. 10, p. E150, doi. 10.1111/hepr.12462
- By:
- Publication type:
- Article
A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial.
- Published in:
- Experimental Hematology & Oncology, 2016, v. 5, p. 1, doi. 10.1186/s40164-016-0040-7
- By:
- Publication type:
- Article
Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma.
- Published in:
- PLoS ONE, 2015, v. 10, n. 2, p. 1, doi. 10.1371/journal.pone.0116842
- By:
- Publication type:
- Article
Magnetic Resonance Evaluation of Multiple Myeloma at 3.0 Tesla: How Do Bone Marrow Plasma Cell Percentage and Selection of Protocols Affect Lesion Conspicuity?
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0085931
- By:
- Publication type:
- Article
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors.
- Published in:
- PLoS ONE, 2013, v. 8, n. 12, p. 1, doi. 10.1371/journal.pone.0083905
- By:
- Publication type:
- Article
Clinical Significance of sIL-2R Levels in B-Cell Lymphomas.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0078730
- By:
- Publication type:
- Article
Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2014, v. 14, n. 1, p. 12, doi. 10.1016/j.clml.2013.12.012
- By:
- Publication type:
- Article
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
- Published in:
- European Journal of Clinical Pharmacology, 2016, v. 72, n. 2, p. 153, doi. 10.1007/s00228-015-1967-z
- By:
- Publication type:
- Article
Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS/MM.
- Published in:
- International Journal of Cancer, 2014, v. 135, n. 4, p. 934, doi. 10.1002/ijc.28731
- By:
- Publication type:
- Article
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.
- Published in:
- International Journal of Hematology, 2020, v. 112, n. 2, p. 243, doi. 10.1007/s12185-020-02855-4
- By:
- Publication type:
- Article
Correction to: A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- corrected article
A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Cell adhesion-induced phosphorylation and inactivation of EZH2 confer drug resistance to acute myeloid leukemia cells.
- Published in:
- 2018
- By:
- Publication type:
- Letter
Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase-9 is not.
- Published in:
- British Journal of Haematology, 2007, v. 139, n. 1, p. 41, doi. 10.1111/j.1365-2141.2007.06721.x
- By:
- Publication type:
- Article
Survival of Multiple Myeloma Patients Aged 65-70 Years in the Era of Novel Agents and Autologous Stem Cell Transplantation.
- Published in:
- Acta Haematologica, 2014, v. 132, n. 2, p. 211, doi. 10.1159/000357394
- By:
- Publication type:
- Article
AMP‐activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR‐ABL protein in CML cells.
- Published in:
- Cancer Science, 2021, v. 112, n. 1, p. 194, doi. 10.1111/cas.14698
- By:
- Publication type:
- Article
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan.
- Published in:
- EJHaem, 2022, v. 3, n. 3, p. 838, doi. 10.1002/jha2.534
- By:
- Publication type:
- Article